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Abstract
A new recombinant form representing a mosaic of HIV-1 subtype B and F1 and designated as CRF42_BF was
identified in Luxembourg. We confirmed the inedited nature of CRF42_BF by near full-length genome char-
acterization and retrieved a possible ancestor originating from Brazil. The demographic history of CRF42_BF
in Luxembourg using Bayesian coalescent-based methods was investigated. The exponential phase of the
logistic growth happened in a very short time period of approximately 5 months associated with a high mean
rate of population growth of 15.02 new infections per year. However, CRF42_BF was not characterized by
either a higher ex vivo replication capacity in peripheral blood mononuclear cells (PBMCs) or a higher ex vivo
transmission efficiency from monocyte-derived dendritic cells to PBMCs as compared to B and F1 viruses.
These data do not support a high pathogenic potential of CFR42_BF but rather an initial bursting spread of the
recombinant probably due to a more favorable transmission route.
The HIV-1 pandemic originated in Central Africa
1 and
was introduced in Europe in the early 1970s. Initially
dominated by subtype B during the first two decades of the
epidemic, the molecular diversity of HIV-1 has been in-
creasing in Western Europe. Population movements and in-
teractions accentuate such a trend, which can be at the origin
of new recombination events between HIV-1 strains. Some
prevalent intersubtype recombinants denoting circulating
recombinant forms (CRFs) are of epidemic importance such
as CRF01_AE and CRF02_AG in Asia and West/Central
Africa, respectively.
Although the global distribution of HIV-1 subtypes is
mainly driven by socioeconomic changes and immigration,
the regional expansion of certain variants is likely related to
virus attributes and opportunity for infection by using a
specific route of transmission.1 It has been assumed that
higher or lower fitness and transmissibility may explain the
success or failure, respectively, of distinctive subtypes in
different regions.2 Because of its particular geographic lo-
cation and because of one of the highest net migration rates
worldwide, Luxembourg is particularly prone to HIV-1 di-
versification.3 Analysis of the B subtype phylogeography
revealed that Luxembourg is a migratory target and imports
viral diversity from abroad.4 In this context, surveillance of
HIV-1 molecular epidemiology is of high importance and a
systematic approach to subtype new HIV-1 viruses in the
country was undertaken.
The proportion of non-B viruses in newly diagnosed
HIV-1 cases has steadily increased in Luxembourg from 20%
to 62% in the past decade. Specifically, newly diagnosed
infections with subtype G, C, and CRF02_AG were signifi-
cantly more frequent due to the natural epidemiological link
existing between Luxembourg and Portugal or Cape Verde
for subtype G and due to the recent sub-Saharan immigration
for subtype C and CRF02_AG. A dramatic increase in the
incidence of HIV-1 unique recombinant forms (URFs) has
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been observed since 2001, with more than 20% of the newly
diagnosed patients being infected with URFs. Interestingly, a
large part of those recombinant strains was represented by a
new B/F1 mosaic virus structure detected in 39 patients since
June 2003.
Baseline plasma samples of the first 21 patients infected
with a typical B/F1 pol pattern from June 2003 to October
2006 were sequenced on ABIPrism 3130xl, using the BigDye
terminator cycle-sequencing chemistry (PE Applied Bio-
systems, Belgium). To obtain near full-length sequence in-
formation, RNA was subjected to multiple polymerase chain
reactions (PCRs) generating overlapping subgenomic frag-
ments. PCR products were sequenced on both strands using
multiple primers. Sequencing primer sequences and PCR
protocols are available on request. The near full consensus
sequence of this new strain was obtained by manual con-
catenating of the partial sequences using the graphic multiple
sequence alignment editor SeaView v.3.2.5
Phylogenetic analysis, using the maximum likelihood ap-
proach under a GTR +G substitution model, was applied to
the three longest near full-length CRF42_BF sequences
(9126–9151 bp) complemented by the Los Alamos National
Laboratory (LANL) 2010 subtype reference set. The phylo-
genetic tree of the three clinical isolates revealed the mono-
phyletic origin of this newly identified CRF, forming a cluster
distinct from previously described B/F1 common recombi-
nant forms ( b F1Fig. 1). The mosaic structure of the B/F1 re-
combinant was determined on the consensus sequence of
the 21 near full-length sequences with jpHMM.6 As shown
in b F2Fig. 2, the majority of the B/F1 genome is B, with three
FIG. 1. Midpoint rooted phylogenetic tree with the three longest near full-length CRF42_BF sequences (luBF 14.05, luBF
17.05, and luBF 01.03) complemented by two of each pure and B/F CRF subtypes from the 2010 LANL reference set. The
maximum likelihood tree was constructed with RAxML 8.0.17 using the GTR+G model. Visualization was done with the
online iTOL tool. Values on the branches represent the percentage of the bootstrap analysis performed on 1,000 replicates (only
values over 70% are shown). GenBank accession numbers are shown on the right side of the dot symbol for each sequence.
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segments of subtype F1 in the gag–pol region (1 kbp), in the
C2–V5 region (0.6 kbp), and in the gp41 ectodomain (0.28
kbp). The new recombinant structure was designated as
CRF42_BF in the Los Alamos HIV sequence database.
The inedited characteristics of the B/F1 recombinant
strains identified in Luxembourg were confirmed using
RDP37 and Recco8 showing that the breakpoints identified in
the sequences were not identical to those of CRF12, 17, 28,
29, 38–40, 44, 46, and 47_BF (data not shown). The very low
genetic diversity observed between the 21 isolates was fur-
ther suggestive of the explosive nature of this small epidemic,
for which a unique introduction event could be assumed.
Indeed, the first 12 patients were diagnosed within the first
year. Since then the incidence of CRF42_BF cases has been
constant, with an average of three new cases per year through
December 2013. All patients reported sexual transmission (8
homosexual and 31 heterosexual transmissions). At diagno-
sis, all the patients presented a mean viral load and CD4 cell
count comparable with the mean of the HIV Luxembourg
cohort (data not shown).
Most of the CRF42_BF infections were believed to have
occurred in Luxembourg rather than having been imported
from outside the country. After systematic review of our
sequences, we were unable to link the isolated B or F1 seg-
ments representing the recombinant to potential parental
viruses in Luxembourg. All viral sequences from the Euro-
pean Nucleotide Archive longer than 250 bp (n = 1,431,749)
were subtyped with COMET9 to find other potential
CRF42_BF sequences. Eleven candidates were further sub-
jected to a bootstrap analysis with the HIV-1 LANL 2010
subtype reference set (1,000 replicates, Jukes–Cantor cor-
rection, neighbor-joining trees) and showed at least 97%
bootstrap support with CRF42_BF. The earliest sequence, a
possible ancestor of CRF42_BF collected during the period
of 1986–2001, originates from Brazil, a country character-
ized by a high frequency of B/F1 recombinants.
As one of the first patients infected with CRF42_BF re-
ported a sexual contact with a partner originating from Brazil
in 2003 in Luxembourg, it is tempting to speculate that the
CRF was imported from this country. The other 10 sequences
originate from different cities in France and were collected
between 2006 and 2010. Furthermore, one sequence from
Italy was reported to cluster with low bootstrap values with
CRF42, indicating other potential introductions of CRF42_
BF in Europe.10 In addition, CRF42_BF was identified be-
tween 2005 and 2013 in two individuals fromArlon (Belgium)
and four from Nancy (France), two cities bordering Lux-
embourg. The former sequences were clustered within the
sequences from Luxembourg, suggesting the spread of the
viruses from Luxembourg (data not shown).
Estimates of the substitution rate and the time of the most
recent common ancestor (MRCA) for the 21 near full se-
quences of CRF42_BF were inferred using a Bayesian
Markov Chain Monte Carlo (MCMC) method implemented
in the BEAST v1.6.1 program.11 The adequacy of the con-
vergence was assessed by determining the effective sampling
size (ESS) and by visual inspection of the MCMC runs with
the Tracer v1.5 program (http://beast.bio.ed.ac.uk/Tracer).
Each MCMC analysis was run for 100 million steps and
sampled every 10,000 states. The best-fit parametric model of
population dynamics for the 21 near full sequences of
CFR42_BF was that of a logistic growth under a relaxed
molecular clock and this model was applied to a larger num-
ber of PROT-RT sequences from 35 CFR42_BF-infected
patients. The mean substitution rate was estimated as 2.66 or
4.04· 10- 3 nucleotide substitutions per site per year according
FIG. 2. Recombinant anal-
ysis of the circulating re-
combinant form CRF42_BF.
(A) Posterior probabilities of
subtype B and F1 calculated
by jpHMM. (B) Map of the
subtype mosaic pattern based
on HXB2 coordinates. The re-
combination breakpoints were
determined with jpHMM.
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to the set of sequences analyzed (T1c Table 1). This substitution
rate is similar to Brazilian subtype B and F1 rates12 or to
Argentinean B/F recombinants previously described as one
of the highest substitution rates for HIV-1.13 The date of the
MRCA was estimated as May 2002 (95% HPD: August
2001–December 2002) or to July 2002 according to the full-
length or pol sequences dataset, respectively. A high mean
rate of population growth of 15.02 new infections per year
(95% HPD: 2.25–34.92) was observed, equating to a mean
epidemic doubling time of 0.56 months (Table 1), which, to
our knowledge, has never been previously reported for
HIV-1. A nonparametric model Bayesian Skyline Plot (BSP)
then assessed the CRF42_BF demographic history.
F3c Figure 3 displays the effective number of infections as a
function of time for the two datasets: the 21 near full-length
genome sequences and the 35 PROT-RT sequences. The ef-
fective number of infections represents the number of infec-
tions actually contributing to new infections. Both curves show
a typical logistic growth with a rapid initial increase and are
largely superimposable. When considering only the 21 full-
genome sequences, the abrupt increase in effective population
size was better ascertained. The exponential phase of the lo-
gistic growth happened in a very short time period of ap-
proximately 5 months and might be suggestive of a high
pathogenic potential of CFR42_BF.
B/F recombinants became the predominant genetic forms
in Latin American countries where subtype B was predomi-
nant before the introduction of subtype F1. It has been pro-
posed that a subtype B and F recombination could provide a
higher fitness compared with a pure subtype B and F1 strain.14
We hypothesized that the high growth rate displayed by the
new variant could be related to its fitness in terms of replication
and/or transmission capacity. CFR42_BF viruses were strictly
R5 variants as determined by their V3 sequences submitted to
geno2pheno coreceptor for coreceptor tropism prediction. We
therefore investigated the ex vivo replicative capacity of R5-
tropic CFR42_BF and phylogenetically related R5-tropic B
and F1 subtypes from Luxembourg by selecting 16 patients
infected with either CRF42_BF or B and F1 subtypes from
2003 to 2006 at diagnosis with a viral load > 20 000 cp/ml.
Frozen virus stocks of six CFR42_BF, six B, and four
F1 primary isolates were expanded in short-term cultures of
PHA/IL-2-treated PBMCs (Red Cross, Luxembourg) to in-
fect PBMCs and monocyte-derived dendritic cells (MO-DCs).
For replication capacity assays, PBMCs were infected and
viral replication was monitored for 15 days using p24
FIG. 3. Bayesian skyline plots
representing nonparametric esti-
mates of the effective number of
infections through time for the
CRF42_BF outbreak in Luxembourg,
using the 21 near full-length genome
(black line) and the 35 PROT-RT
genes (gray line). Median estimate of
the effective number of infections
(solid line) and 95% confidence
limits of the estimate (dashed lines)
are shown. The vertical axes repre-
sent the estimated effective number
of infections on a logarithmic scale.
The time scale is in calendar years.
Table 1. Bayesian Estimates of CRF42_BF Population Dynamics
Parameter Estimate HPD (95%) (lower–upper)
Mean substitution ratea
21 full-length sequences 4.04 · 10- 3 2.91 · 10- 3–5.14 · 10- 3
35 PROT-RT sequences 2.66 · 10- 3 1.37 · 10- 3–4.13 · 10- 3
MRCA
21 full-length sequences July 2002 November 2001–January 2003
35 PROT-RT sequences May 2002 August 2001–December 2002
Mean population growth rateb
21 full-length sequences 15.02 2.25–34.92
Mean epidemic doubling timec
21 full-length sequences 0.55 3.68–0.24
aNumber of substitutions per site per year.
bNumber of new infections per year.
c(Month).
MRCA, most recent common ancestor.
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concentrations of cell-free viral supernatant measured every
3 days (Perkin-Elmer, United Kingdom). CRF42_BF strains
were not characterized by a higher replication capacity as
compared to B or F1 viruses, which could explain the rapid
spread of the new CRF ( p> 0.05, data not shown). These re-
sults are in agreement with a recent study showing that a
similar replicative fitness was shared between subtype B and
a B/F recombinant from Argentina.15
To evaluate transmission efficiency, CD14 + monocytes
were isolated from PBMCs by negative selection using the
DynabeadslMyPure Monocyte Kit 2 (Invitrogen) according
to the manufacturer’s protocol to achieve a purity of 95% of
monocytes. Monocytes were further maturated for 7 days with
IL-4 and GMC-SF (20 ng/ml each) to obtain MO-DCs
(CD13+ high, CD11c+ high, CD80+ high, CD86+ high,
HLA-DR+ , and CD83 low), and infected with 0.001 TCID50
of each virus. Autologous frozen PBMCs were added and
cultured for 12 days. The p24 antigen was measured at days 5
and 12 and the CRF42_BF viruses did not show a significantly
higher in vitro transmission efficiency than B or F1 viruses
( p> 0.05, data not shown). Consequently, we might assume
that CRF42_BF was rapidly introduced in Luxembourg be-
tween 2003 and 2006 probably due to a more favorable
transmission route rather than by aggressive viral behavior.
Taken together, our population history analysis gives a
coherent view of a local epidemic in which the number of
cases at least tripled within a few years and remained stable
since. We showed that the CRF42_BF outbreak displayed a
fast initial growth phase that was not due to superior repli-
cative fitness or transmission efficiency. Ultimately, our
study illustrates the increasing molecular complexity of
HIV-1 in Luxembourg.
Nucleotide Sequences Accession Numbers
CRF42_BF from Luxembourg: EU170135-155, KJ739817-
838. CRF42_BF from Brazil: AY569830. CRF42_BF from
France: HQ718234, HQ718277, JQ292572–JQ292577,
JN642564. CRF42_BF from Arlon, Belgium: KJ719554-5.
CRF42_BF from Nancy, France: KJ739835-8.
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